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Avoiding graft-vs.-host disease (GVHD)' while retaining the engraftment-pro-
moting and antileukemic effects ofT cells in allogeneic marrow remains a major
challenge in the field of bone marrow transplantation (BMT) . WhileT cell deple-
tion reduces the incidence ofGVHD, it is associated with an increased probability
ofengraftment failure (1-6) and agreater risk ofleukemic relapse (4, 5, 7) . Previous
work from this laboratory has demonstrated that the GVHD-related mortality of
lethally irradiated, bone marrow-reconstituted mice can be delayed by the coad-
ministration ofT cell-depleted (TCD) syngeneic marrow (8). Although this result
was encouraging, we have found themagnitude ofthe protection from acuteGVHD
mortality to be limited, and no protection from chronicGVHD mortality has been
apparent (8). We therefore sought a method of augmenting this protective effect
ofTCD syngeneic marrow. We have previously demonstrated that TCD syngeneic
marrow is responsible for most of the natural suppressor (NS) activity arising in
spleens of lethally irradiated mice reconstituted with a mixture of allogeneic plus
syngeneic marrow, and have hypothesized that such cells might be responsible for
the anti-GVHD effect of TCD syngeneic marrow (9) . Since cell lines with in vitro
NS activity and in vivo anti-GVHD effects have been successfully cultured in IL-2
(10, 11 ; SykesM., K. A. Hoyles, M. L. Romick, andD . H. Sachs, manuscript in
preparation), we wished to address the possibility that the administration of IL-2
in vivo to lethally irradiated, bone marrow-transplanted mice might increase the
anti-GVHD effect ofTCD syngeneic bone marrow. Our results indicate that IL-2
provides significant protection againstGVHD mortality from allogeneic lympho-
cytes whilepermitting complete repopulation by allogeneic bone marrow cells(BMC) .
When suboptimal amounts of IL-2 were given, maximal protection was achieved
when TCD syngeneic marrow was also administered . Survivors protected in this
manner similarly demonstrated complete allogeneic reconstitution .
Address correspondence to Megan Sykes, Transplantation Biology Section, Immunology Branch, Na-
tional Cancer Institute, Building 10, Room 4B13, National Institutes of Health, Bethesda, MD 20892 .
1 Abbreviations used in this paper . BMC, bone marrow cells ; BMT, bone marrow transplantation; FCM,
flow cytometry;GVHD, graft-vs.-host disease ; LAK, lymphokine-activated killer;NSy natural suppressor;
TCD, T cell depleted .
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Materials and Methods
Animals.
￿
Male and female C57BL/10SnJ (1110, H-26, KbIbSbDb), B10.D2/nSn (1110.132,
H-2d, KdIdSdDd), and A/J (H-2a, KIIISdDd) mice were obtained from The Jackson Labora-
tory Bar Harbor, ME, or from the Frederick Cancer Research Facility ofthe National Cancer
Institute.
BMT .
￿
BMT was performed as previously described (12). Briefly, recipient B10 mice, aged
12-16 wk, were lethally irradiated (1,025 rad, 137Cs source, 110 rad/min) and reconstituted
within 8-12 h with BMC obtained from the tibiae and femora of sex-matched donors aged
6-14 wk. Animals were housed in sterilized microisolator cages, in which they received au-
toclaved food and autodaved acidified drinkingwater. Syngeneic (1110) bone marrow was TCD
using rabbit anti-mouse brain serum, as previously described (12). 1-1.5 x 10' untreated
fullyMHC-mismatched allogeneic (B10.D2 or A/J) BMC were administered with or without
allogeneic spleen cells, varying in dose from 6.5 x 106 (A/J spleen cells) to 3.5 x 10' (B10.D2
spleen cells). All BMC and spleen cells were coadministered in a single 1-ml intravenous in-
jection. Irradiation controls received no BMC or spleen cells and died 7-12 d afterirradiation.
To avoid any cage-related effects on experimental results, animals were randomized both
before assigning the experimental groups, and after BMT, so that animals from different
experimental groups were randomly mixed in each cage. Survival was checked on a daily
basis for 100 d.
IL-2Administration.
￿
The indicated doses ofhuman rIL-2, kindly provided by Cetus Corp.
(Emeryville, CA), were injected intraperitonealiy in 0.2 ml of HBSS. Unless otherwise indi-
cated, the first dose of IL-2 was administered 1-3 h before BMT, and approximately every
12 h thereafter, for a total of 10 doses. As a control for IL-2 toxicity, additional irradiated
animals received IL-2 plus TCD syngeneic marrow with or without allogeneic marrow, and
without allogeneic spleen cells.
mAbs.
￿
FITC-conjugated mAb 5F1 (anti-Kb) (13) and biotinylated mAb 34-2-12 (anti-Dd)
(14) were prepared by standard methods using antibodies purified from ascites usingprotein
A-Sepharose 411 beads (Pharmacia Fine Chemicals, Uppsala, Sweden).
Phenotyping of Chimeras.
￿
Phenotyping was performed 9-15 wk after BMT Animals were
bled and PBMC were isolated as described (12). PBMC from each animal were then split
into two tubes, and staining with mAbs was performed as described (15). Staining with both
donor-specific and host-specific mAbs was performed on each chimera and control animal.
One-color flow cytometry (FCM) was performed as described (16). In all experiments, per-
cent staining was determined from one-color fluorescence histograms and comparison with
those obtained from normal donor and host-type animals, which were used as positive and
negative controls. The percentage of cells considered positive after staining with a mAb was
determined using a cutoff for positivity chosen as the fluorescence level at the beginning of
the positive peak of the positive control strain. The relative percent staining of a chimera
with a mAb was calculated using the formula: 100 x (chimera percent positive) - (negative
control percent positive)/(positive control percent positive) - (negative control percent posi-
tive). Since the mAbs used were allele specific for class I H-2 antigens, nearly 100% of cells
from positive control animals, and 0% of cells from negative control animals, stained with
each mAb in every experiment.
StatisticalAnalysis.
￿
Survival probability was determinedusing the censored data technique
of Kaplan-Meier, and statistical significance was determined usingthe method of Wilcoxon
and Breslow. Since this method of analysis attributes increased weight to the early portion
ofa survival curve, a two-tailed stratifiedlog rank survival test was substituted when the ques-
tion of protection from late mortality was specifically being addressed. All statistical results
are expressed as p values, and values <0.05 are considered to be significant.
Results
Effects of IUD Syngeneic Marrow and IL-2 on Mortalityfrom Moderate GVHD.
￿
The
results in Fig. 1 show the effects of TCD syngeneic marrow and IL-2 on mortality
from a moderately severe GVHD, which caused early mortality in one third of con-SYKES ET AL.
￿
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trol animals. The survival oflethally irradiated B10 control mice given 1.5 x 101
A/J BMC plus 8 x 10' A/J spleen cells is shown by the solid line in Fig. 1, B-D.
All animals presumably succumbed to GVHD, since control animals not receiving
A/J spleen cells demonstrated excellent survival (Fig. 1 A). The results in Fig. 1 B
demonstrate that, while TCD syngeneic marrow prevented early GVHDmortality,
all animals eventually succumbed to chronic GVHD, and theoverall survival curve
wasnot significantlydifferent from thatofthe controls. However, similartoprevious
reports (17), GVHD mortality occurred in two phases, including an acute phase
in which deaths occurredbetweendays 7 and 15, and amore chronic phase, usually
beginning after day 30. We therefore performed separate statistical analyses on the
two phases of the survival curves. Analysis of the early portion of the curves (i.e.,
the first 25 d) revealed a statistically significant (p < 0.02) protective effect ofTCD
syngeneicmarrowagainst mortality. When the results ofthis experimentwere com-
binedwith three others involving similarlymild early GVHDmortality, a significant
protective effect ofTCDsyngeneicmarrowwasagaindemonstrated (datanot shown).
The effect ofIL-2 administration on GVHD mortality is shown in Fig. 1 C. In
these animals, IL-2 was found to protect against both early and late GVHD mor-
tality (Fig. 1 C; p < 0.008).
Fig. 1 D shows the effect of combined treatment with TCD syngeneic marrow
plus IL-2, 50,000 U twice daily from days 0 to 4, on GVHD mortality. This com-
bined regimen significantly reduced both early and late GVHD mortality, so that
63% ofanimals survived >100 d, compared with only 7° Jo survival among animals
receivingneither IL-2 nor TCDsyngeneic marrow (p < 0.0006). Similarprotection
from late GVHD mortality by this treatment regimen has been reproducibly ob-
served in another strain combination, B10.D2 into BIO (p < 0.003 for the combined
results ofthreeexperiments; n = 27 in each group). Although the difference in sur-
vival between the groups receiving IL-2 with or without TCD syngeneic marrow
did not achieve statistical significance, long-term survival was slightly greater in
recipients ofTCD syngeneic marrow(63 vs. 46%), possibly reflecting the improved
protection from acute GVHD seen in the group receivingTCD marrow(see below).
In two additional experiments comparing chronic GVHD mortality in animals
receiving IL-2 with or without TCD syngeneic marrow, the late mortality curves
of both groups were also similar (see below).
Effects ofTCD SyngeneicMarrow and IL-2 on Mortalityfrom Severe GVHD.
￿
We next
examined the effects ofIL-2 on acute mortality due to a more potent GVHD. In
most experiments, administration of>8 x 10' A/J spleen cells was sufficient to kill
control recipients before day 15, as is shown by the solid line in Fig. 2, B-D, for
animals receiving 1.1 x 101 A/J BMC plus 9 x 106 A/J spleen cells. Since animals
receivingBMC without spleen cells demonstrated excellent survival (Fig. 2A), mor-
tality was most likely due to GVHD. As shown in Fig. 2 B, administration ofTCD
syngeneic marrow without IL-2 had no effect on the rapid mortality from this A/J
lymphocyte inoculum (p > 0.05), and similar results have been observed in most
experiments in which the majority of control animals died in the acute phase of
GVHD. The effects of IL-2 on such mortality in mice receiving A/J cells with or
without TCD syngeneic marrow were examined. The results in Fig. 2 C show that
IL-2 (10,000 U twice daily for 5 d) provided no protection against acute GVHD
mortality when given without TCD syngeneic marrow (p > 0.05). In contrast, ad-648
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FIGURE 1 .
￿
Effect of IL-2 andTCDsyngeneic marrow onGVHD mortality from A/J lympho-
cytes . Lethally irradiated B10 mice received 8 x 106 A/J spleen cells plus 1.5 x 10' A/J BMC,
with or without 5 x 106TCD B10 BMC, and IL-2, 50,000 U, i.p., twice daily for 5d . (A) Sur-
vival of control animals not receiving A/J spleen cells; (") TCD B10 alone (n = 5) ; (") TCD
B10BMCplus IL-2 (n = 5) ; (p)TCDB10BMC plus A/JBMC (n = 5); (A)TCD B10BMC
plus A/JBMC plus IL-2 (n = 5) ; (O) A/J BMC (n = 2) ; (A) A/J BMC plus IL-2 (n = 3) .
(B, C, and D) (
￿
) The survival of animals receiving only A/J BMC plus spleen cells
(n = 15) . (B) ( - - - ) Survival curve of animals receivingA/JBMC plus spleen cells plusTCD
B10BMC (n = 15). (C) (- - -) Survival curve of animals receivingA/JBMCplus spleen cells
plus IL-2 (n = 15) . (D) (- - -) Survival curve ofanimals receivingA/JBMC plus spleen cells,
plus TCD B10 BMC plus IL-2 (n = 14) .
ministration o£TCD syngeneic marrow plus IL-2 was associated with significant
protection from GVHD mortality (Fig . 2 D; p< 0.02) . Thus, coadministration of
TCD syngeneic marrow and IL-2 was necessary to protect against mortality from
thepotent GVHD observed in this experiment . In an additional experiment in which
IL-2 alone did not provide optimal protection, a similar effect ofTCD syngeneic
marrow was observed (data not shown) . In other experiments, IL-2 alonewascapable
of producing marked protection against acute GVHD mortality (e.g., Fig. 3) .
Nevertheless, maximal early survival was achieved in recipients ofTCD syngeneic
marrow along with IL-2 in five of five experiments (e.g., Figs . 2 and 3) .SYKES ET AL .
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FIGURE 2 .
￿
Effect of IL-2 andTCD syngeneicmarrow on rapid, acuteGVHD mortality pro-
duced by A/jlymphocytes . Lethally irradiated B10 mice received 9 x 106A/j spleen cells plus
1.1 x 10' A/j BMC, with or without 5 x 106TCD B10BMC and IL-2, 10,000Utwice daily
for 5 d . (A) Survival of control animals not receiving A/j spleen cells ; (`)TCD B10BMC plus
IL-2 (n - 3);(O)TCD B10BMC plus A/jBMC (n = 3) ; (A) TCD B10BMC plus A/jBMC
plus IL-2 (n - 5). (B, C, andD) (
￿
)The survival ofanimals receivingA/jBMCand spleen
cells alone (n = 10) . (B) (- - - ) Survival curve ofanimals receivingA/jBMC plus spleen cells
plus TCDB10BMC (n = 9) . (C) ( - - - ) Survival curve for animals receivingA/jBMCplus
spleen cells plus IL-2 (n = 9) . (D) ( - - - ) Survival curve for animals receivingA/jBMC plus
spleen cells plus TCD B10BMC and IL-2 (n = 9) .
Relationship ofIL-2 Dose to Prevention ofGVHD Mortality.
￿
We examined the dose-
response relationship of IL-2 and protection fromGVHD mortality. In four of five
experiments thedegree ofprotection from acuteGVHD mortalitywas directlypropor-
tional to the dose of IL-2 administered . These results are summarized in Table I;
the difference in mortality in recipients of the 10,000- vs . the 50,000-U dose was
significant, but only reflected differences in acute GVHD mortality (see 25-d sur-
vival, Table I) . Only a small difference in long-term survival was apparent between
the two groups, suggesting an increase in chronic GVHD mortality in recipients
ofthehigher, compared with thelower, IL-2 dose (100-d survival, Table I). The mag-
nitude of the acute protective effect in a fifth experiment was inversely proportional650
￿
INTERLEUKIN 2 PREVENTS GRAFT-VS.-HOST DISEASE MORTALITY
100
A eo
so
70
> so
so
40
30
20
10
0
B 100
00
so
70 a
>_ so
e0
~! 40
30
20
10
0
0 1'0 20 30 40 s0
-------
1
_---
.... .. ... ... . ... .
TIME (DAYS)
FIGURE 3.
￿
IL-2 alone prevents acuteGVHD mortality,
but maximalearly survival is achieved in recipients of
TCDsyngeneicmarrow plus IL-2. (A andB) Twoinde-
pendentexperiments showingsurvivalin lethally irradi-
atedmice reconstituted withsimilarinocula containing
A/J BMC plus A/J spleen cells, along with: no addi
tional treatment(
￿
); TCDsyngeneicmarrow coad-
ministered in the reconstituting inoculum on day 0
( - - - ); IL-2, 50,000 U twicedailyon day0-4 (A) or
day0-2(B)( . . . . . ); IL-2, 50,000 Utwicedailyon day
0-4(A)or day0-2(B)plus TCDsyngeneicmarrow coad-
ministered in the reconstituting inoculum on day 0
(- -) Each groupcontained8-10 animals. Control
animalsnotreceivingA/J spleen cellsdemonstrated ex-
cellent survival in both experiments.
to the dose (10,000, 25,000, or 50,000 U twice daily for 5 d) of IL-2 administered.
We considered this result to be dueto aberrant IL-2 toxicity (discussed below), and
therefore elected not to include this experiment in the summarypresented in Table
I. Control animals receiving TCD syngeneic marrow and/or A/J marrow with or
without IL-2 demonstrated uniformly excellent survival (data not shown).
TABLE I
Dose-Response Relationship of IL-2 and GVHD Mortality
(BI0(-T) BM + AIJ BM + AIJ Spleen - B10)
No. of survivors
" The indicated dose wasadministered twicedaily for 5 d, beginning immedi-
ately before BMT.
t MST, median survival time determined from Kaplan-Meier plots.
S P value comparing group above and below the indicated value. For group
receiving 50,000 U IL-2, P< 0.0001, compared with groupnotreceiving IL-2.
All Pvalues were determined using the method of Wilcoxon and Breslow.
IL-2 dose'
U
Day 25
%
Day 100
%
MSTI
d
Ps
0 (n - 38)
10,000 (n = 38)
50,000 (n - 35)
6 (16)
21 (55)
32 (91)
5 (13)
14 (37)
16 (46)
9
47
89
<0.002
<0.03Elect of Timing ofIL-2 Administration on GVHD Prevention.
￿
Several investigators
have reported that in vivo administration ofIL-2 is associated with acceleration of
GVHD mortality (17-19). One possible explanation for this discrepancy with our
own results was that IL-2 was administered by thoseworkersfor aprolonged period,
or was begun with a delay of 7 or 8 d after BMT (17, 18), whereas we began IL-2
administrationon the day ofBMT and completed the treatment after 5 d. To assess
this possibility, we compared survival in lethally irradiated B10 recipients ofTCD
B10 marrow plus A/J BMC and spleen cells without IL-2, or with 10,000 U IL-2
administered twicedaily for5d beginningeither on theday ofirradiation andBMT,
or 7 d later. The results, shown in Fig. 4, indicate that IL-2 was protective only
when administration was begun on the day of BMT (;6 < 0.01). Administration of
IL-2 beginning on day 7 was associated with a significant acceleration of GVHD
mortality (lb < 0.0005), consistent with previous reports (17, 18). Similarresultswere
obtained in a repeat experiment using the higher dose of IL-2 (50,000 U).
Although the first dose ofIL-2 was administered immediatelybefore BMT in all
experimentsreported here, such timing was not critical, since additionalexperiments
demonstrated that delaying administration until 1 h after BMT did not reduce the
anti-GVHD effect of IL-2 (data not shown). Administration of a single high dose
ofIL-2 (immediately preceeding BMT) did not protect against acute GVHD mor-
tality (Fig. 5).
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5 d (n = 5), demonstrated 100% survival.
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FIGURE 4.
￿
Effect oftiming ofIL-2 administration
on GVHD mortality. Lethally irradiated B10 mice
received 5 x 106 TCD B10 BMC, 101 A/J BMC,
and 9 x 106 A/J spleen cells. (
￿
) Survival of
control animals not receiving IL-2 (n = 10); ( - - - )
survival of animals receiving 10,000 U IL-2 twice
daily for 5 d beginning on the day of BMT (n =
10); ( . . . . . ) survival ofanimals receiving 10,000 U
ofIL-2 twice daily for 5 d beginning 7 d after BMT
(n = 10). Control animals (not shown; n = 5)
receiving A/J marrow plus TCD syngeneic marrow
demonstrated 100% survival.
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Since animals in some experiments began to appear illon the fourth day ofhigh-
dose (50,000 U) IL-2 administration, showing lethargy, hunching, and ruffled fur,
it seemed possible that this dose of IL-2 might be producing cumulative toxicity.
We therefore examined theeffect ofa shortened 2.5-d(five dose) course ofhigh-dose
IL-2 on GVHD mortality. As shown in Fig. 5, this shortened course was at least
as protective against early GVHD mortality as wasafull 5-d course, and the animals
showed no clinical evidence for adverse effects. Similar results were obtained in a
repeat experiment. Also, no differences in latermortalityhave been seen after a 100-d
follow-up.
Effect ofIL-2 on Engraftment.
￿
To examine the effects of IL-2 on alloengraftment,
the PBL oflong-term BMT survivors were phenotyped using mAbs and FCM. No
differences were observed in the level ofallogeneic reconstitution between animals
receiving or not receiving IL-2 (10,000-50,000 Utwice daily for 5 d for one or two
courses) along with allogeneic (A/J or BMW) spleen cells, BMC, and TCD syn-
geneic marrow. Examples of FCM profiles from such animals are shown in Fig. 6.
Most animalsin all groups, regardless ofwhether or notspleen cells were administered,
demonstrated complete allogeneic lymphopoietic repopulation, similarto the results
shown in Fig. 6. In some animals receiving IL-2 plus allogeneic BMC and TCD
syngeneic BMC without allogeneic spleen cells, however, a small, negative peak
representing -1-10% of cells was evident on staining with antibody recognizing
donor H-2 antigens. This negative peak corresponded to apositivepeak on staining
with antibody recognizing host H-2 antigens, and tended to disappear with time;
such host-type cells were detected in six of seven recipients tested before day 70,
and in only 5 of27 such animals tested after day 95. 1 of 13 simultaneous control
B10 B10.D2 FIGURE 6. Examples of the
phenotype of lymphopoietic
cells repopulating lethally ir-
radiated B10mice treatedor not
treated with IL-2, 50,000 U
twicedailyfor5 dbeginningon
thedayofBMT B10micewere
lethally irradiated and recon-
stituted with either TCD 1110
BMC plus B10.D2 BMC, or
with TCD B10 BMC, 1110.132
BMC, and1110.132 spleen cells,
or with B10.D2 BMC and
spleen cells alone, as indicated.
PBLwere obtained 15 wk after
BMT, stained with mAbs, and
analyzed using FCM, as indi-
cated in Materials and Meth-
ods. Staining with Kb-specific
mAb 5171 (---); staining
with Dd-specific mAb 34-2-12
NO IL2 +IL2
8101-TIBM + B10.D2BM ~n\
B10.D2BM + B10.D2Spleen IV
B101-T)BM + B10.D2BM +
1
r\ / B10MSpleenSYKES ET AL.
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recipients ofTCD syngeneic marrow and allogeneic marrow without IL-2 demon-
strated such a peak. Of 21 animals receiving allogeneic spleen cells in addition to
TCD syngeneic marrow, allogeneic marrow, and IL-2, none showed any evidence
for repopulation by host-type cells at any time.
Discussion
In this report we demonstrate that IL-2 administered in vivo at the time of BMT
has a potent effect in preventing mortality due to both acute and chronicGVHD.
Furthermore, the combination of IL-2 and TCD syngeneic marrow provides op-
timal protection against acute GVHD mortality. Neither IL-2 alone nor IL-2 plus
TCD syngeneic marrow prevented complete lymphopoietic reconstitution by coad-
ministered allogeneic BMC plus spleen cells. This novel method of achieving com-
plete allogeneic lymphopoietic repopulation whilereducingGVHD mortality presents
a possible solution to the opposing problems ofGVHD versus failure ofalloengraft-
ment associated with T cell depletion forthe prevention ofGVHD (1-6). The possi-
bility that administration of IL-2 might still permit, and even add to (20), the an-
tileukemic effects of allogeneic T cells (4, 5, 7, 21) is currently being explored in
a murine leukemia model, which we have recently described (22).
Previous reports from this laboratory demonstrated that TCD syngeneic marrow
can delay mortality from acute GVHD (8). In the experiments reported here, we
have detected a protective effect ofTCD syngeneic marrow against acute GVHD
only when the GVHD was mild in severity (e.g., Fig. 1). Furthermore, consistent
with theprevious report (8), TCD syngeneic marrow alone didnot preventlate mor-
tality from chronicGVHD. Thus, TCD syngeneic marrow alone hasalimitedability
to prevent acute GVHD mortality and no detectable effect on chronicGVHD. In
contrast, the addition of high doses of IL-2 leads to increased protection from acute
GVHD mortality (e.g., Figs. 2, 4, and 5), as well as significant protection from chronic
GVHD mortality (e.g., Fig. 1). Protection from chronic GVHD mortality is ap-
parent regardless of whether or not TCD syngeneic marrow is coadministered.
In the absence ofTCD syngeneic marrow, IL-2 also has significant protective ac-
tivity against acute GVHD mortality, but, in every instance, such protection was
less than that observed when TCD syngeneicmarrow was coadministered (e.g., Figs.
2 and 3). The ability ofTCD syngeneic marrow to increase the protective effect
in recipients of IL-2 was most apparent in experiments in which IL-2 aloneprovided
suboptimal protection (e.g., Fig. 2). In some experiments, the degree of protection
afforded by IL-2 alone was so potent that there was little room for improvement
by the addition ofTCD syngeneic marrow (e.g., Fig. 3) . The reasons for the vari-
ability in the degree ofprotection afforded by similar doses of IL-2 alone are as yet
unclear. If this model were to be applied to larger animals or man, it is possible
that IL-2 toxicity would prevent the administration ofoptimal doses, in which case,
the improved protection provided by the addition ofTCD autologous marrow might
be desirable.
Our data suggest that activation or generation by IL-2 of a cell population con-
tained in TCD syngeneic marrow, such as lymphokine-activated killer (LAK) cells
(23-25), NS cells (23, 26), or veto cells (23, 27), might play a role in protecting from
GVHD mortality. Both NK and LAKcellshave been shownto be activated by treat-
ment with IL-2 in vivo (28-31). Such cell populations in syngeneic marrow might654
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suppress a GVH response better than similar populations in allogeneic marrow be-
cause oftheir abilityto preferentially killallogeneic and not syngeneiclymphoblasts
(32), or to preferentially suppress responsesdirected against antigens shared by the
suppressive population (9, 23, 27). The weaker effect ofIL-2 in the absence ofTCD
syngeneic marrow could reflect the activation ofresidual cell populations in the ir-
radiated host, or ofcell populations in allogeneic BMC and spleens with the ability
to suppress GVH reactions in an antigen-nonspecific manner.
Our results appear to conflict with those of other workers, who have found that
GVHD ispotentiated, rather than abrogated, by invivo administrationofIL-2 (17-19).
This discrepancycould bedue to severaldifferences in thesystemsstudied, including
the fact that theseworkersdid not coadminister TCD syngeneic marrow, administered
lower doses of IL-2 (17-19), and used a delayed or prolonged time course of IL-2
administration (17, 18). Consistent withthispossibility, we observed protectionwhen
IL-2 was administered for 5 d starting on day 0, but acceleration ofmortality when
administration ofthe same dose was begunafter a7-d delay. Thus, IL-2 maypoten-
tiate GVHD once T cellshave already become sensitized, but may prevent or abort
the sensitization ofpreviously unprimed T cells. Indeed, IL-2 may be a mediator
ofthe anti-GVHD effect of CD4+ allogeneic T cells observed by Sprent et al. (17)
in a class I difference-only GVHD.
Additional possible mechanisms for the anti-GVHD effect ofIL-2 include more
rapid hematopoietic recovery induced by IL-2 (33), which may be secondary to the
production ofhematopoietic growth factors by activated NK cells (34). IL-2 may
improve resistance to infection through the antiviral, antifungal, antiprotozoan, or
antibacterial activities ofactivated NK cells (35, 36), or by promoting the develop-
ment ofother immunocompetent cell populations; such activities might be highly
protective, since infection has been found to play a pivotal role in the induction of,
and morbidity from, GVHD (37, 38). The ability of IL-2 to prevent GVHD mor-
tality long after completion of such therapy suggests that protection is either due
to theinductionofa protective cell population by IL-2, orto the permanent deletion
ofGVH-reactive clones from the original allogeneic splenocyte inoculum. Experi-
ments are currently underway to distinguish between these possibilities.
Inone offivedose-response titrations intheA/JintoB10 strain combination, greater
protection was provided by decreasing, rather than increasing, doses of IL-2. Al-
though we cannot explain this variability between experiments, these results, the
apparent illness of some animals after the third day of high-dose IL-2 treatment,
and the observation that IL-2 therapy beginningon day 7 leads to accelerated mor-
tality, suggested that a shortercourse ofhigh-dose IL-2 might optimize survival by
limiting IL-2 toxicity or by diminishing the exacerbation ofGVHD associated with
IL-2 administration at latertimes afterBMT The results ofsuch an approach (Fig.
5) support this notion, and such a protocol may prove to be optimal for avoiding
both GVHD and IL-2 toxicity.
We have obtained preliminary evidence for a transient, early increase in NK ac-
tivity in the spleens ofsome, but not all, lethally irradiated mice receivingIL-2 and
TCD syngeneic marrow (data not shown). Since NK cells have been found to play
a rolein mediatingIL-2 toxicity (39), resisting alloengraftment(40-42), and effecting
GVHD-related injury (43), it will be important to dissect the role, if any, of NK
cellsin the phenomenadescribedhere. Despitetheincrease inNKactivity observedSYKES ET AL.
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in some animals, complete allogeneic repopulation was achieved in all long-term
survivors reconstituted with TCD syngeneic marrow, allogeneic marrow, and al-
logeneic spleen cells.
In summary, we have presented a new approach to the avoidance of mortality from
acute and chronic GVHD that does not prevent alloengraftment. Attempts to un-
derstand the mechanism of this effect, and to apply it in a leukemic model (22),
will help to determine its potential for clinical application.
Summary
Previous work from this laboratory has demonstrated that T cell-depleted (TCD)
syngeneic marrow can delay, but not prevent, the mortality from acute graft-vs.-
host disease (GVHD) caused by MHC-mismatched lymphoid cells administered
to lethally irradiated mice. We demonstrate here that a protective effect against GVHD
is also observed after in vivo treatment with IL-2. Administration of 10,000-50,000 U
of IL-2 twice daily for the first 5 d after bone marrow transplantation markedly re-
duced the mortality from both acute and chronic GVHD induced across complete
MHC barriers in lethally irradiated mice, and frequently led to long-term survival.
Complete allogeneic reconstitution was demonstrated in all long-term survivors of
this treatment regimen. While either IL-2 or TCD syngeneic marrow administered
alone was protective in some experiments, the maximal protective effect was ob-
served after administration ofboth IL-2 and TCD syngeneic marrow, especially when
the effects of IL-2 were suboptimal. The timing of IL-2 administration was critical
to this beneficial effect, since a delay of 7 d in commencing IL-2 treatment was as-
sociated with accelerated GVHD mortality. This new approach to the prevention
ofGVHD permits the administration of allogeneic T cells, and may therefore avoid
the increased incidence of graft failure and loss of antileukemic effects associated
with the T cell depletion of allogeneic marrow, which is otherwise required for the
prevention of GVHD.
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